121 related articles for article (PubMed ID: 1344831)
1. [Omeprazole and liver functions].
Sauvet P; Schouler L
Rev Med Interne; 1992; 13(5):359-63. PubMed ID: 1344831
[TBL] [Abstract][Full Text] [Related]
2. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450.
Diaz D; Fabre I; Daujat M; Saint Aubert B; Bories P; Michel H; Maurel P
Gastroenterology; 1990 Sep; 99(3):737-47. PubMed ID: 2136526
[TBL] [Abstract][Full Text] [Related]
3. [Omeprazole and the cytochrome P450 system of the liver].
Petersen KU
Leber Magen Darm; 1993 Sep; 23(5):186-92. PubMed ID: 8412467
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole.
Humphries TJ
Dig Dis Sci; 1991 Dec; 36(12):1665-9. PubMed ID: 1748033
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
6. Omeprazole: pharmacology, pharmacokinetics and interactions.
Oosterhuis B; Jonkman JH
Digestion; 1989; 44 Suppl 1():9-17. PubMed ID: 2691315
[TBL] [Abstract][Full Text] [Related]
7. The anti-secretory effect and pharmacokinetics of omeprazole in chronic liver disease.
McKee RF; MacGilchrist AJ; Garden OJ; Forrest JA; Carter DC
Aliment Pharmacol Ther; 1988 Oct; 2(5):429-37. PubMed ID: 2979265
[TBL] [Abstract][Full Text] [Related]
8. Lack of pantoprazole drug interactions in man.
Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
Int J Clin Pharmacol Ther; 1994 Aug; 32(8):385-99. PubMed ID: 7981922
[TBL] [Abstract][Full Text] [Related]
9. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
10. Omeprazole drug interaction studies.
Andersson T
Clin Pharmacokinet; 1991 Sep; 21(3):195-212. PubMed ID: 1764870
[TBL] [Abstract][Full Text] [Related]
11. Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
[TBL] [Abstract][Full Text] [Related]
12. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
13. [The second generation of gastric antisecretory agents: omeprazole].
Souquet JC
Rev Med Interne; 1988; 9(5):538-44. PubMed ID: 3067302
[TBL] [Abstract][Full Text] [Related]
14. Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a trisphenylcarbamoylcellulose-based stationary phase. The effect of the enantiomers of omeprazole on gastric glands.
Erlandsson P; Isaksson R; Lorentzon P; Lindberg P
J Chromatogr; 1990 Nov; 532(2):305-19. PubMed ID: 2084128
[TBL] [Abstract][Full Text] [Related]
15. Proton-pump inhibition for acid-related disease.
Holt S
South Med J; 1991 Sep; 84(9):1078-87. PubMed ID: 1653998
[TBL] [Abstract][Full Text] [Related]
16. Omeprazole: pharmacokinetics and metabolism in man.
Cederberg C; Andersson T; Skånberg I
Scand J Gastroenterol Suppl; 1989; 166():33-40; discussion 41-2. PubMed ID: 2690330
[TBL] [Abstract][Full Text] [Related]
17. Omeprazole, a proton pump inhibitor, reduces the secretion, synthesis and gene expression of pepsinogen in the rat stomach.
Kakei N; Ichinose M; Tsukada S; Tatematsu M; Tezuka N; Yahagi N; Matsushima M; Miki K; Kurokawa K; Takahashi K
Biochem Biophys Res Commun; 1993 Sep; 195(2):997-1004. PubMed ID: 7690564
[TBL] [Abstract][Full Text] [Related]
18. Cimetidine and omeprazole accelerate gastric ulcer healing by an increase in gastrin secretion.
Ito M; Segami T; Inaguma K; Suzuki Y
Eur J Pharmacol; 1994 Oct; 263(3):253-9. PubMed ID: 7843262
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of rat gastric mucosal response to potent acid inhibition.
Nørsett KG; Laegreid A; Langaas M; Wörlund S; Fossmark R; Waldum HL; Sandvik AK
Physiol Genomics; 2005 Jun; 22(1):24-32. PubMed ID: 15827235
[TBL] [Abstract][Full Text] [Related]
20. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments.
Funck-Brentano C; Becquemont L; Lenevu A; Roux A; Jaillon P; Beaune P
J Pharmacol Exp Ther; 1997 Feb; 280(2):730-8. PubMed ID: 9023285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
